Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

Results from the International BRCA1/2 carrier cohort study

Antonis C. Antoniou, Matti Rookus, Nadine Andrieu, Richard Brohet, Jenny Chang-Claude, Susan Peock, Margaret Cook, D. Gareth Evans, Rosalind Eeles, Catherine Nogues Embrace, Laurence Faivre, Paul Gesta, Genepso Flora E Van Leeuwen, Margreet G E M Ausems, Ana Osorio Geo-Hebon, Trinidad Caldes, Jacques Simard, Jan Lubinski, Anne Marie Gerdes, E. Oláh & 6 others Christine Fürhauser, Hakan Olsson, Brita Arver, Paolo Radice, Douglas F. Easton, David E. Goldgar

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Background: Several reproductive and hormonal factors are known to be associated with ovarian cancer risk in the general population, including parity and oral contraceptive (OC) use. However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies. Methods: We used data on 2,281 BRCA1 carriers and 1,038 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study to evaluate the effect of reproductive and hormonal factors on ovarian cancer risk for mutation carriers. Data were analyzed within a weighted Cox proportional hazards framework. Results: There were no significant differences in the risk of ovarian cancer between parous and nulliparous carriers. For parous BRCA1 mutation carriers, the risk of ovarian cancer was reduced with each additional full-term pregnancy (P trend = 0.002). BRCA1 carriers who had ever used OC were at a significantly reduced risk of developing ovarian cancer (hazard ratio, 0.52; 95% confidence intervals, 0.37-0.73; P = 0.0002) and increasing duration of OC use was associated with a reduced ovarian cancer risk (P trend = 0.0004). The protective effect of OC use for BRCA1 mutation carriers seemed to be greater among more recent users. Tubal ligation was associated with a reduced risk of ovarian cancer for BRCA1 carriers (hazard ratio, 0.42; 95% confidence intervals, 0.22-0.80; P = 0.008). The number of ovarian cancer cases in BRCA2 mutation carriers was too small to draw definitive conclusions. Conclusions: The results provide further confirmation that OC use, number of full-term pregnancies, and tubal ligation are associated with ovarian cancer risk in BRCA1 carriers to a similar relative extent as in the general population.

Original languageEnglish
Pages (from-to)601-610
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Ovarian Neoplasms
Cohort Studies
Mutation
Oral Contraceptives
Tubal Sterilization
Confidence Intervals
Pregnancy
Parity
Population

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers : Results from the International BRCA1/2 carrier cohort study. / Antoniou, Antonis C.; Rookus, Matti; Andrieu, Nadine; Brohet, Richard; Chang-Claude, Jenny; Peock, Susan; Cook, Margaret; Evans, D. Gareth; Eeles, Rosalind; Embrace, Catherine Nogues; Faivre, Laurence; Gesta, Paul; Van Leeuwen, Genepso Flora E; Ausems, Margreet G E M; Geo-Hebon, Ana Osorio; Caldes, Trinidad; Simard, Jacques; Lubinski, Jan; Gerdes, Anne Marie; Oláh, E.; Fürhauser, Christine; Olsson, Hakan; Arver, Brita; Radice, Paolo; Easton, Douglas F.; Goldgar, David E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 2, 02.2009, p. 601-610.

Research output: Contribution to journalArticle

Antoniou, AC, Rookus, M, Andrieu, N, Brohet, R, Chang-Claude, J, Peock, S, Cook, M, Evans, DG, Eeles, R, Embrace, CN, Faivre, L, Gesta, P, Van Leeuwen, GFE, Ausems, MGEM, Geo-Hebon, AO, Caldes, T, Simard, J, Lubinski, J, Gerdes, AM, Oláh, E, Fürhauser, C, Olsson, H, Arver, B, Radice, P, Easton, DF & Goldgar, DE 2009, 'Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 carrier cohort study', Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 2, pp. 601-610. https://doi.org/10.1158/1055-9965.EPI-08-0546
Antoniou, Antonis C. ; Rookus, Matti ; Andrieu, Nadine ; Brohet, Richard ; Chang-Claude, Jenny ; Peock, Susan ; Cook, Margaret ; Evans, D. Gareth ; Eeles, Rosalind ; Embrace, Catherine Nogues ; Faivre, Laurence ; Gesta, Paul ; Van Leeuwen, Genepso Flora E ; Ausems, Margreet G E M ; Geo-Hebon, Ana Osorio ; Caldes, Trinidad ; Simard, Jacques ; Lubinski, Jan ; Gerdes, Anne Marie ; Oláh, E. ; Fürhauser, Christine ; Olsson, Hakan ; Arver, Brita ; Radice, Paolo ; Easton, Douglas F. ; Goldgar, David E. / Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers : Results from the International BRCA1/2 carrier cohort study. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 2. pp. 601-610.
@article{6d6d9234c56f4e49b8f5f5536f0180f8,
title = "Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 carrier cohort study",
abstract = "Background: Several reproductive and hormonal factors are known to be associated with ovarian cancer risk in the general population, including parity and oral contraceptive (OC) use. However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies. Methods: We used data on 2,281 BRCA1 carriers and 1,038 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study to evaluate the effect of reproductive and hormonal factors on ovarian cancer risk for mutation carriers. Data were analyzed within a weighted Cox proportional hazards framework. Results: There were no significant differences in the risk of ovarian cancer between parous and nulliparous carriers. For parous BRCA1 mutation carriers, the risk of ovarian cancer was reduced with each additional full-term pregnancy (P trend = 0.002). BRCA1 carriers who had ever used OC were at a significantly reduced risk of developing ovarian cancer (hazard ratio, 0.52; 95{\%} confidence intervals, 0.37-0.73; P = 0.0002) and increasing duration of OC use was associated with a reduced ovarian cancer risk (P trend = 0.0004). The protective effect of OC use for BRCA1 mutation carriers seemed to be greater among more recent users. Tubal ligation was associated with a reduced risk of ovarian cancer for BRCA1 carriers (hazard ratio, 0.42; 95{\%} confidence intervals, 0.22-0.80; P = 0.008). The number of ovarian cancer cases in BRCA2 mutation carriers was too small to draw definitive conclusions. Conclusions: The results provide further confirmation that OC use, number of full-term pregnancies, and tubal ligation are associated with ovarian cancer risk in BRCA1 carriers to a similar relative extent as in the general population.",
author = "Antoniou, {Antonis C.} and Matti Rookus and Nadine Andrieu and Richard Brohet and Jenny Chang-Claude and Susan Peock and Margaret Cook and Evans, {D. Gareth} and Rosalind Eeles and Embrace, {Catherine Nogues} and Laurence Faivre and Paul Gesta and {Van Leeuwen}, {Genepso Flora E} and Ausems, {Margreet G E M} and Geo-Hebon, {Ana Osorio} and Trinidad Caldes and Jacques Simard and Jan Lubinski and Gerdes, {Anne Marie} and E. Ol{\'a}h and Christine F{\"u}rhauser and Hakan Olsson and Brita Arver and Paolo Radice and Easton, {Douglas F.} and Goldgar, {David E.}",
year = "2009",
month = "2",
doi = "10.1158/1055-9965.EPI-08-0546",
language = "English",
volume = "18",
pages = "601--610",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

T2 - Results from the International BRCA1/2 carrier cohort study

AU - Antoniou, Antonis C.

AU - Rookus, Matti

AU - Andrieu, Nadine

AU - Brohet, Richard

AU - Chang-Claude, Jenny

AU - Peock, Susan

AU - Cook, Margaret

AU - Evans, D. Gareth

AU - Eeles, Rosalind

AU - Embrace, Catherine Nogues

AU - Faivre, Laurence

AU - Gesta, Paul

AU - Van Leeuwen, Genepso Flora E

AU - Ausems, Margreet G E M

AU - Geo-Hebon, Ana Osorio

AU - Caldes, Trinidad

AU - Simard, Jacques

AU - Lubinski, Jan

AU - Gerdes, Anne Marie

AU - Oláh, E.

AU - Fürhauser, Christine

AU - Olsson, Hakan

AU - Arver, Brita

AU - Radice, Paolo

AU - Easton, Douglas F.

AU - Goldgar, David E.

PY - 2009/2

Y1 - 2009/2

N2 - Background: Several reproductive and hormonal factors are known to be associated with ovarian cancer risk in the general population, including parity and oral contraceptive (OC) use. However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies. Methods: We used data on 2,281 BRCA1 carriers and 1,038 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study to evaluate the effect of reproductive and hormonal factors on ovarian cancer risk for mutation carriers. Data were analyzed within a weighted Cox proportional hazards framework. Results: There were no significant differences in the risk of ovarian cancer between parous and nulliparous carriers. For parous BRCA1 mutation carriers, the risk of ovarian cancer was reduced with each additional full-term pregnancy (P trend = 0.002). BRCA1 carriers who had ever used OC were at a significantly reduced risk of developing ovarian cancer (hazard ratio, 0.52; 95% confidence intervals, 0.37-0.73; P = 0.0002) and increasing duration of OC use was associated with a reduced ovarian cancer risk (P trend = 0.0004). The protective effect of OC use for BRCA1 mutation carriers seemed to be greater among more recent users. Tubal ligation was associated with a reduced risk of ovarian cancer for BRCA1 carriers (hazard ratio, 0.42; 95% confidence intervals, 0.22-0.80; P = 0.008). The number of ovarian cancer cases in BRCA2 mutation carriers was too small to draw definitive conclusions. Conclusions: The results provide further confirmation that OC use, number of full-term pregnancies, and tubal ligation are associated with ovarian cancer risk in BRCA1 carriers to a similar relative extent as in the general population.

AB - Background: Several reproductive and hormonal factors are known to be associated with ovarian cancer risk in the general population, including parity and oral contraceptive (OC) use. However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies. Methods: We used data on 2,281 BRCA1 carriers and 1,038 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study to evaluate the effect of reproductive and hormonal factors on ovarian cancer risk for mutation carriers. Data were analyzed within a weighted Cox proportional hazards framework. Results: There were no significant differences in the risk of ovarian cancer between parous and nulliparous carriers. For parous BRCA1 mutation carriers, the risk of ovarian cancer was reduced with each additional full-term pregnancy (P trend = 0.002). BRCA1 carriers who had ever used OC were at a significantly reduced risk of developing ovarian cancer (hazard ratio, 0.52; 95% confidence intervals, 0.37-0.73; P = 0.0002) and increasing duration of OC use was associated with a reduced ovarian cancer risk (P trend = 0.0004). The protective effect of OC use for BRCA1 mutation carriers seemed to be greater among more recent users. Tubal ligation was associated with a reduced risk of ovarian cancer for BRCA1 carriers (hazard ratio, 0.42; 95% confidence intervals, 0.22-0.80; P = 0.008). The number of ovarian cancer cases in BRCA2 mutation carriers was too small to draw definitive conclusions. Conclusions: The results provide further confirmation that OC use, number of full-term pregnancies, and tubal ligation are associated with ovarian cancer risk in BRCA1 carriers to a similar relative extent as in the general population.

UR - http://www.scopus.com/inward/record.url?scp=60549104788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549104788&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0546

DO - 10.1158/1055-9965.EPI-08-0546

M3 - Article

VL - 18

SP - 601

EP - 610

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -